Justin Gregg, MD, on the Use of the Mediterranean Diet in Men With Localized Prostate Cancer
The assistant professor of Urology at The University of Texas MD Anderson Cancer Center spoke about the results of a study which evaluated the use of the Mediterranean diet in men with localized prostate cancer on active surveillance.
The Mediterranean diet was revealed to be associated with a lower risk of Gleason Grade group progression among men with localized prostate cancer on active surveillance, according to a study (NCT00490763) published in Cancer.
These findings are consistent with previous reports of the Mediterranean diet, resulting in reductions in cancer morbidity and mortality. However, follow-up in larger studies of men enrolled on active surveillance are still necessary to verify patient- and cancer-specific effects of adherence to the Mediterranean diet in men with early-stage prostate cancer.
In an interview with CancerNetwork®, Justin Gregg, MD, assistant professor of Urology at The University of Texas MD Anderson Cancer Center as well as lead author of the study, discussed these findings and what led he and his colleagues to conduct this research.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences channels.
Reference:
Gregg JR, Zhang X, Chapin BF, et al. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer. Published online January 7, 2020. doi:10.1002/cncr.33182
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
